Mohammed H Alanazy, Khalid A Alghsoon, Abdulaziz F Alkhodairi, Faisal K Binkhonain, Turkey N Alsehli, Feras F Altukhaim, Ibrahim M Alkhodair, Taim Muayqil
{"title":"Public Willingness to Undergo Presymptomatic Genetic Testing for Alzheimer's Disease.","authors":"Mohammed H Alanazy, Khalid A Alghsoon, Abdulaziz F Alkhodairi, Faisal K Binkhonain, Turkey N Alsehli, Feras F Altukhaim, Ibrahim M Alkhodair, Taim Muayqil","doi":"10.1155/2019/2570513","DOIUrl":null,"url":null,"abstract":"<p><p>Presymptomatic genetic testing (PGT) for Alzheimer's disease (AD) is available for at-risk individuals. This study aimed to investigate the public perception of PGT in Saudi Arabia and determine variables that might influence the decision to undergo PGT. A questionnaire link was posted on Twitter by the Saudi Alzheimer's Disease Association and was made publicly available on social media networks. A total of 2935 people participated, of which 59.9% were willing to undergo PGT. Of these, 26.8% reported having a family history of AD, and 0.24% had two family members with early onset AD. The reasons cited for willingness to undergo PGT included the following: to adopt a healthier lifestyle, to ensure appropriate family and financial planning, to seek early treatment, and to relieve anxiety. In multiple logistic regression analysis, willingness to undergo PGT was negatively associated with having a self-reported family history of dementia (OR 0.81, 95% CI 0.68-0.96) and was positively associated with marital status (OR 1.39, 95% CI 1.13-1.70). In conclusion, PGT for AD seems to be well accepted in this large Saudi cohort. The reasons cited are similar to those reported elsewhere in the literature.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2019-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/2570513","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology Research International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2019/2570513","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 4
Abstract
Presymptomatic genetic testing (PGT) for Alzheimer's disease (AD) is available for at-risk individuals. This study aimed to investigate the public perception of PGT in Saudi Arabia and determine variables that might influence the decision to undergo PGT. A questionnaire link was posted on Twitter by the Saudi Alzheimer's Disease Association and was made publicly available on social media networks. A total of 2935 people participated, of which 59.9% were willing to undergo PGT. Of these, 26.8% reported having a family history of AD, and 0.24% had two family members with early onset AD. The reasons cited for willingness to undergo PGT included the following: to adopt a healthier lifestyle, to ensure appropriate family and financial planning, to seek early treatment, and to relieve anxiety. In multiple logistic regression analysis, willingness to undergo PGT was negatively associated with having a self-reported family history of dementia (OR 0.81, 95% CI 0.68-0.96) and was positively associated with marital status (OR 1.39, 95% CI 1.13-1.70). In conclusion, PGT for AD seems to be well accepted in this large Saudi cohort. The reasons cited are similar to those reported elsewhere in the literature.
阿尔茨海默病(AD)的症状前基因检测(PGT)可用于高危人群。本研究旨在调查沙特阿拉伯公众对PGT的看法,并确定可能影响接受PGT决定的变量。沙特阿尔茨海默病协会在推特上发布了一份问卷链接,并在社交媒体网络上公开发布。共有2935人参与,其中59.9%的人愿意接受PGT。其中,26.8%的人报告有AD家族史,0.24%的人有两个家族成员患有早发性AD。愿意接受PGT的原因包括:采取更健康的生活方式,确保适当的家庭和财务规划,寻求早期治疗,以及缓解焦虑。在多元logistic回归分析中,接受PGT的意愿与自我报告的痴呆家族史呈负相关(OR 0.81, 95% CI 0.68-0.96),与婚姻状况呈正相关(OR 1.39, 95% CI 1.13-1.70)。总之,在这个庞大的沙特人群中,PGT治疗AD似乎得到了很好的接受。引用的原因与文献中其他地方的报道相似。
期刊介绍:
Neurology Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies focusing on diseases of the nervous system, as well as normal neurological functioning. The journal will consider basic, translational, and clinical research, including animal models and clinical trials.